跳到正文
营养与代谢随机对照试验3 分钟阅读

在胰岛素基础上加三株益生菌,与1型糖尿病患者血糖改善相关

MoveVitals 编辑部 · 研究发表 · 解读更新

原文:Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus. · Frontiers in endocrinology · 2022 · 论文原文 ↗

先看重点

在6至18岁1型糖尿病患者的双盲试验中,胰岛素基础上加用三株益生菌6个月后,空腹血糖和糖化血红蛋白(HbA1c)较治疗前降低,多种炎症指标下降。益生菌组仅27人,摘要也未给出具体效应数值,这只是早期信号,不能证明确有获益。

证据类型

随机对照试验

解读依据

公开摘要

阅读重点

对照与不确定性

研究在问什么

1型糖尿病(T1DM)是免疫系统破坏胰腺产生胰岛素的β细胞所致,而肠道细菌参与免疫调节。作者检验了在常规胰岛素基础上加用特定益生菌,能否改善血糖控制(HbA1c)和炎症指标,以及益生菌如何改变肠道菌群。

研究了谁,如何研究

在中国医药大学附设医院开展的随机、双盲、安慰剂对照试验(ClinicalTrials.gov编号NCT03880760),纳入6至18岁的T1DM患者。27名患者在常规胰岛素基础上每日服用含唾液乳杆菌AP-32、约氏乳杆菌MH-68和乳双歧杆菌CP-9的胶囊,共6个月;29名患者只用胰岛素、不加益生菌,作为安慰剂组。观察空腹血糖和HbA1c,用酶联免疫吸附法检测促炎与抗炎细胞因子,并用二代测序(NGS)分析粪便菌群。

主要发现

以下为作者报告的结果。数字须连同人群和不确定性一起阅读。

  1. 1
    肠道测序显示,服用益生菌的患者肠道中动物双歧杆菌、嗜黏蛋白阿克曼菌和唾液乳杆菌的数量增加。
  2. 2
    益生菌治疗后空腹血糖较干预前显著降低,HbA1c也有所改善。摘要没有给出具体数值,也未给出与安慰剂组的直接比较。
  3. 3
    益生菌干预后,IL-8、IL-17、MIP-1β、RANTES和TNF-α浓度显著降低,同时TGF-β1表达增加。
  4. 4
    停用益生菌3个月后,血糖控制和免疫调节的改善仍然存在。

局限与不确定性

  1. 1
    这是一项小型试验(益生菌组27人,安慰剂组29人),来自一家医院,且只涉及儿童和青少年。
  2. 2
    血糖结果表述为治疗前后的变化,摘要未给出数值,因此无法判断变化中有多少超出了安慰剂组。
  3. 3
    所用益生菌是三个特定菌株的组合,结果不能推广到其他益生菌产品。
  4. 4
    血糖和细胞因子的变化不能说明并发症或低血糖等长期结局。本解读仅基于摘要。

对日常健康的启示

这项早期试验提示,在胰岛素之外加用特定的益生菌组合,可能改善1型糖尿病青少年的血糖和炎症指标。这并不意味着益生菌能代替或减少胰岛素,三个特定菌株的结果也不能套用到货架上的产品。调整糖尿病治疗前,应与糖尿病团队商量。

如何联系自己的数据

对1型糖尿病患者来说,持续葡萄糖监测(CGM)的达标时间和HbA1c是应该与医疗团队一起关注的数字。建议用同一传感器比较相似的几周,不要因为服用补充剂而自行停用或更改胰岛素。

如何理解这类证据

随机分组有助于因果推断,仍须检查分配、盲法、失访、随访时间和具体对照;标为随机试验不自动意味着高确定性。

作者的结构化摘要 English

以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。

Introduction

Type 1 diabetes mellitus (T1DM) is characterized by autoimmune destruction of pancreatic β cells. Previous study has discovered that probiotic strains residing in the gut play essential roles in host immune regulation. However, few clinical results demonstrated probiotic would actually benefit in attenuating glycated hemoglobin (HbA1c) along with inflammatory cytokine levels of the T1DM patients and analyzed their gut microbiota profile at the same time. In this clinical trial, we evaluated the therapeutic efficacy of probiotics on HbA1c along with inflammatory cytokine levels of T1DM patients to determine an alternative administration mode for T1DM medication. The probiotics changed T1DM gut microbiota profile will be measured by next-generation sequencing (NGS).

Research design and methods

A randomized, double-blind, placebo-controlled trial was performed at China Medical University Hospital. T1DM patients between 6 and 18 years of age were enrolled. 27 patients were administered regular insulin therapy plus capsules containing probiotic strains Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 daily for 6 months, and 29 patients were administered insulin therapy without extra probiotic supplement as placebo group. The variations of fasting blood glucose and HbA1c in these patients were analyzed. In addition, serum levels of inflammatory cytokines and anti-inflammatory cytokine were assessed using enzyme-linked immunosorbent assay. Patients' stool microbiota were all subjects to NGS analysis.

Results

NGS data showed elevated populations of Bifidobacterium animalis, Akkermansia muciniphila and Lactobacillus salivarius in the gut of patients with T1DM who were taking probiotics. Patients with T1DM who were administered probiotics showed significantly reduced fasting blood glucose levels compared with the before-intervention levels. The HbA1c levels of the patients also improved after administration of probiotics. The concentrations of IL-8, IL-17, MIP-1β, RANTES, and TNF-α were significantly reduced and were associated with an increased TGF-β1 expression after probiotic intervention. The persistence effect of glycemic control and immunomodulation were observed even 3 months after discontinuation of the probiotics.

Conclusions

Here, we found that conventional insulin therapy plus probiotics supplementation attenuated T1DM symptoms than receiving insulin treatment only. Probiotics supplementation with insulin treatment changed gut microbiota and revealed better outcome in stabilizing glycemic levels and reducing HbA1c levels in patients with T1DM through beneficial regulation of immune cytokines.

Clinical trial registration

ClinicalTrials.gov, identifier NCT03880760.

来源与署名

Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus.

Wang CH, Yen HR, Lu WL, Ho HH, Lin WY, Kuo YW, Huang YY, Tsai SY, Lin HC.

Frontiers in endocrinology · 2022-03-01

DOI: 10.3389/fendo.2022.754401 ↗PubMed · 35299968 ↗Europe PMC · 记录的开放许可: cc by ↗

摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。

MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅

来源核验日期 2026-11-01

实用健康指南

放在一起读

·随机试验荟萃分析

更早的进食窗口与更大的体重和胰岛素获益相关,优于晚间进食

汇总41项随机对照试验(2287名参与者,干预时间中位数8周)发现,限时进食比日常饮食体重低2.15 kg(95%置信区间−2.56至−1.74),而早吃比晚吃体重多降1.15 kg(95%置信区间−1.86至−0.45)。多数试验较短,只有6个研究组检验了早间进食,结局是身体和血液指标,不是心脏病发作或死亡。

BMJ Medicine

重点论文精讲阅读论文 →
·随机对照试验

限热量饮食再加上午8点至下午4点进食窗口,1年减重无明显额外优势

139名肥胖患者都按限制热量的饮食进食,其中一组再加上上午8:00至下午4:00的进食窗口,12个月平均体重变化为−8.0 kg,单纯限热量组为−6.3 kg。净差值−1.8 kg(95%置信区间−4.0至0.4;P=0.11)无统计学意义,该区间既不能排除窗口确有获益,也不能排除毫无作用。

The New England Journal of Medicine

重点论文精讲阅读论文 →
·随机对照试验

20人住院试验:超加工饮食让人每天多摄入508 kcal并增重

20名成年人在医院研究病房住了28天,两种菜单各吃2周、想吃多少吃多少:超加工菜单让他们每天多摄入508 kcal(±106,标准误,P=0.0001),体重增加0.9 kg;未加工菜单则让体重减轻0.9 kg。样本小、周期短、食物全程由研究方提供,既不能说明日常生活中的长期结果,也无法确定是食物的哪种特点导致多吃。

Cell Metabolism

重点论文精讲阅读论文 →
·随机对照试验

地中海饮食加橄榄油或坚果与心血管事件减少相关(更正后的试验)

在7447名55至80岁、心血管风险较高的西班牙成年人中,被分到加特级初榨橄榄油(风险比0.69,95%置信区间0.53至0.91)或加坚果(风险比0.72,0.54至0.95)的地中海饮食组,发生主要心血管事件的风险低于被告知减少脂肪的对照组。试验存在随机化失误,2013年的报告已撤回并重新估算,证据有力但并不完美。

The New England Journal of Medicine

重点论文精讲阅读论文 →
营养与代谢 →